<DOC>
	<DOCNO>NCT00001637</DOCNO>
	<brief_summary>Diseases leukemia , lymphoma , multiple myeloma fall category blood cancer . Some condition cure bone marrow transplantation ( BMT ) . The ability BMT cure condition credit use high dos chemotherapy , radiation therapy , antileukemia effect transplant . Because effectiveness BMT relies use high dos chemotherapy total body irradiation ( TBI ) , therapy associate toxic side effect . These side effect often deadly limited BMT use patient age 55 . In study researcher plan treat old patient age 55 75 year blood cell transplant take donor genetically match relatives patient . In order decrease toxic side effect associate transplant , researcher use chemoradiotherapy . Instead plan use intensive immunosuppressive therapy allow transplant cell take effect .</brief_summary>
	<brief_title>Immunosuppressive Preparation Followed Blood Cell Transplant Treatment Blood Cancers Older Adults</brief_title>
	<detailed_description>Patients adult leukemia , non-Hodgkin 's lymphoma multiple myeloma , cure allogeneic bone marrow transplantation ( BMT ) . This curative effect ascribe use high dose chemoradiotherapy antileukemia effect graft . The assumption BMT rely myeloablative effect high dose chemotherapy total body irradiation ( TBI ) , largely restrict allogeneic bone marrow transplantation adult age 55 year . Toxicity related mortality increase progressively age although transplant center carry BMT patient age 60 year , generally accept treatment related mortality prohibits use allogeneic bone marrow transplantation patient beyond age 55 year . Several vitro study demonstrate existence donor-derived CD4 CD8 positive lymphocyte specific reactivity patient leukemia potent graft versus leukemia ( GVL ) effect . This GVL effect best see patient relapse CML bone marrow transplantation single infusion donor lymphocytes induce complete remission . In protocol , treat old patient age 55 71 year hematologic disorder allogeneic stem cell transplant HLA identical sibling , use intensive immunosuppressive regimen without myeloablation attempt decrease transplant related toxicity preserve antileukemia effect graft . The low intensity nonmyeloablative conditioning regimen provide adequate immunosuppression allow stem cell lymphocyte engraftment . T-cell replete , donor-derived , granulocyte colony stimulate factor ( G-CSF ) mobilize peripheral blood stem cell ( PBSC ) use establish hematopoietic lymphoid immune reconstitution . We add back lymphocytes patient less 75 % donor marrow chimerism attempt prevent graft rejection . The end point study engraftment , degree donor-host chimerism , incidence acute chronic GVHD , transplant relate morbidity mortality well survival .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>INCLUSION CRITERIA PATIENT : Ages 5571 year . Chronic myelogenous leukemia ( CML ) : chronic phase . Acute lymphoblastic leukemia ( ALL ) , patient complete partial remission . Acute myelogenous leukemia ( AML ) : AML first complete partial remission . Exceptions : AML good risk karyotype : AML M3 ( 5 ; 17 ) , AML M4Eo ( inv . 16 ) , AML ( 8 ; 21 ) . All AML second subsequent complete remission . Myelodyplastic syndrome : refractory anemia excess blast ( less 10 % ) early transformation acute leukemia Chronic myelomonocytic leukemia . Chronic lymphocytic leukemia ( CLL ) bulky progressive disease despite prior treatment chemotherapy include purine analog . Mantle cell lymphoma . Relapsed progressive nonHodgkins lymphoma , fail standard treatment approach unsuitable autologous stem cell transplantation . No major organ dysfunction preclude transplantation . DLCO great equal 40 % predict . Left ventricular ejection fraction : great 30 % predict . ECOG performance status 02 . INCLUSION CRITERIA DONOR : HLA identical family donor , 75 year old . Fit receive GCSF give peripheral blood stem cell ( normal blood count , normotensive , history stroke , history severe heart disease ) . Informed consent give . EXCLUSION CRITERIA : Patient donor pregnant lactating . Patient age less 55 , great 71 year . ECOG performance status 3 . Psychiatric disorder mental deficiency patient donor sufficiently severe make compliance BMT treatment unlikely , make informed consent impossible . Major anticipated illness organ failure incompatible survival BMT . DLCO le 40 % predict . Left ventricular ejection fraction le 30 % predict . Serum creatinine great 2.5 mg/dl . Serum bilirubin great 4 mg/dl , transaminases great 5 time upper limit normal . HIV positive ( donor recipient ) . Donors positive HBV , HCV , HTLV use discretion investigator . Other malignant disease liable relapse progress within 5 year . Donor unfit receive GCSF undergo apheresis . ( Uncontrolled hypertension , history heart failure unstable angina , platelet count le 90,000/cu mm ) .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>71 Years</maximum_age>
	<verification_date>December 28, 2016</verification_date>
	<keyword>Peripheral Blood Stem Cells</keyword>
	<keyword>Engraftment</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Nonmyeloablative</keyword>
	<keyword>Graft-Versus-Leukemia</keyword>
	<keyword>Graft v . Host Disease</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Donor Apheresis</keyword>
	<keyword>Nonmyeloablative Bone Marrow Transplantation</keyword>
	<keyword>Chronic Myelogenous Leukemia ( CML )</keyword>
	<keyword>Acute Lymphoblastic Leukemia ( ALL )</keyword>
	<keyword>Acute Myelogenous Leukemia ( AML )</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Chronic Lymphocytic Leukemia ( CLL )</keyword>
	<keyword>Prolymphocytic Leukemia</keyword>
</DOC>